Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XDx, a molecular diagnostics company, has signed a collaborative pharmacogenomics agreement with Bristol-Myers Squibb Company.
Subscribe to our email newsletter
The collaboration is focused on identifying biomarkers in the field of systemic lupus erythematosus for clinical diagnostic purposes associated with the clinical development of Orencia, a Bristol-Myers Squibb drug approved for the treatment of rheumatoid arthritis.
Bristol-Myers Squibb will make an upfront payment to XDx in addition to milestone payments upon the successful achievement of specific R&D objectives. XDx will receive commercial rights to certain diagnostic applications resulting from the collaboration.
Pierre Cassigneul, president and CEO of XDx, said: “We are pleased to be working with our new partners at Bristol-Myers Squibb and we intend to continue leveraging our R&D, clinical, and bioinformatics capabilities through partnerships to further demonstrate the utility of our innovative biomarker identification technologies and diagnostic work in autoimmune disease.”